HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
HIND
Vyome Holdings, Inc.
There isn't enough reported data to score HIND yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
HIND Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
HIND's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
HIND PE Valuation
HIND has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
HIND Forward outlook
There aren't enough analyst estimates for HIND to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIND has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus HIND down 100%.
HIND Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$226,722.00 | +$953,578.00 |
| Q2 2023 | -$371,606.00 | +$1,087,094.00 |
| Q1 2023 | -$510,342.00 | +$939,658.00 |
| Q4 2022 | -$628,894.00 | +$1,076,306.00 |
| Q3 2022 | -$1,180,300.00 | -$84,100.00 |
| Q2 2022 | -$1,458,700.00 | -$617,700.00 |
| Q1 2022 | -$1,450,000.00 | -$275,500.00 |
| Q4 2021 | -$1,705,200.00 | -$321,900.00 |
HIND lost $1,527.07 per share over the past year, a smaller loss than the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over HIND on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over HIND on profitability, with a higher operating margin.
HIND Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $58K | +67% |
| Q2 2026 | $27K | -98% |
| Q1 2026 | $31.6K | -97% |
| Q4 2025 | $36.6K | -98% |
| Q3 2025 | $34.6K | -98% |
| Q2 2025 | $1.2M | -37% |
| Q1 2025 | $1.1M | -43% |
| Q4 2024 | $1.8M | -8.9% |
HIND's revenue is recovering but still below its 2021 peak: $57,998 last quarter, up 67% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1761% | +23001 points |
| Q2 2026 | -3200% | -2978 points |
| Q1 2026 | -3577% | -3379 points |
| Q4 2025 | -3707% | -3613 points |
| Q3 2025 | -24762% | -24685 points |
| Q2 2025 | -222% | -118 points |
| Q1 2025 | -198% | -85 points |
| Q4 2024 | -94% | +1.3 points |
HIND's operating margin was −1761% last quarter, up 23001 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over HIND on cash generation, producing positive trailing cash flow while its opponent burns cash.
HIND Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$627.6K | -114% |
| Q2 2026 | -$903.7K | +$3.6M |
| Q1 2026 | -$1.4M | +$683K |
| Q4 2023 | -$2.5M | +$452K |
| Q3 2023 | -$2.8M | +$2.5M |
| Q2 2023 | -$6.7M | -$264K |
| Q1 2023 | -$5.1M | +$2.3M |
| Q4 2022 | -$2.9M | +$584K |
HIND has burned cash in almost every quarter: −$4M over the past year, against −$5M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over HIND on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
HIND Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.3% | +67 shares |
| 1 year | +767% | +4.6K shares |
| 3 years | +18314% | +5.1K shares |
HIND has 5,156 diluted shares, up 767% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
HIND Net Leverage
HIND's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
HIND Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.9 | Oversold |
| Stochastic | 12.6 | Oversold |
HIND's weekly RSI is 28 (oversold) and its Stochastic is 13 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
HIND PE vs Healthcare Sector
HIND has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
HIND Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.84 | 11% below |
| 20 week MA | $2.04 | 20% below |
| 50 week MA | $2.43 | 33% below |
| 100 week MA | $47.1 | 97% below |
| 200 week MA | $3,472.6 | 100% below |
HIND is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over HIND on returns for 2026, with the stronger performance.
HIND Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1,644,300.0 | $1,383,300.0 | -16% |
| 2021 | $1,383,300.0 | $574,200.0 | -58% |
| 2022 | $574,200.0 | $35,612.0 | -94% |
| 2023 | $35,612.0 | $1,450.0 | -96% |
| 2024 | $1,450.0 | $455.0 | -69% |
| 2025 | $455.0 | $3.73 | -99% |
| 2026 YTD | $3.73 | $1.63 | -56% |
HIND has finished every year since 2020 lower, and it's down 56% so far in 2026.